Medical Science Liaison (Carolinas)

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess an advanced degree in health sciences (PharmD, MD, or PhD) with at least 2 years of experience in hematologic malignancy or cell therapy, or a Master's degree with extensive clinical/medical affairs experience. A minimum of 2 years of MSL/Medical Affairs experience in a relevant therapeutic area is required. Familiarity with healthcare systems and access environments, strong partnering and influencing skills, excellent communication and presentation abilities, personal integrity, and adaptability are essential. The candidate must reside within the Carolinas territory.

Responsibilities

The Medical Science Liaison will establish and maintain relationships with healthcare professionals in the hematology space, develop and execute territory plans, and compliantly partner with field-based teams. Responsibilities include delivering approved medical and scientific education, collecting insights from thought leaders to inform medical strategies, representing the company at conferences, and supporting clinical trial execution. Approximately 50-70% domestic travel is required.

Skills

Cell Therapy

Medical Affairs

Scientific Exchange

Medical Education

Thought Leader Engagement

Insight Collection

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free